VCEL
Vericel Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website vcel.com
- Employees(FY) 305
- ISIN US92346J1088
Performance
-0.62%
1W
+1.75%
1M
-1.73%
3M
+35.89%
6M
+35.78%
YTD
+47.14%
1Y
Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: VCEL
Overview
VCEL is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $2.35 billion. In this report, we will conduct a comprehensive analysis of VCEL's financial statements over the past three years, including balance ...
Technical Analysis of VCEL 2024-05-10
Overview:
In analyzing the technical indicators for VCEL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...
Recent News & Updates
- 2024-05-09 15:28
- 2024-05-09 08:24
Vericel First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-09 03:28
- 2024-05-09 03:08
- 2024-05-08 23:24
Q1 2024 Vericel Corp Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-08 09:35
- 2024-05-08 09:10
- 2024-05-08 07:55
- 2024-05-07 19:55
- 2024-04-26 06:40
- 2024-04-24 08:30
- 2024-04-23 20:30
- 2024-04-23 20:00
VCEL: Lowering target price to $49.00(Argus Research)
- 2024-04-13 08:24
Vericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Even(Simply Wall St.)
- 2024-03-29 19:01
- 2024-03-28 13:48
Land Developer And A Specialty Medical Stock Burst Into Buy Zones(Investor's Business Daily)
- 2024-03-15 19:00
- 2024-03-03 07:53
- 2024-03-02 07:48
Vericel Full Year 2023 Earnings: EPS Beats Expectations(Simply Wall St.)
- 2024-03-01 09:30
- 2024-03-01 06:44
- 2024-02-29 23:37
Q4 2023 Vericel Corp Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-29 09:05
- 2024-02-29 08:32
- 2024-02-29 07:55
- 2024-02-28 20:05
- 2024-02-28 18:55
- 2024-02-27 08:30
- 2024-02-26 19:30
- 2024-02-26 11:29
3 Top Pharma Stocks for Investors Betting on a Biotech Boom(InvestorPlace)
Page 1 of 6
previousnext